XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.2

Notes to the Consolidated Statements of Operations - Additional Information (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Notes to the Consolidated Statements of Operations
Revenue recognized	€ 7,579	€ 20,146	€ 14,708	€ 44,519
Milestone revenues
Notes to the Consolidated Statements of Operations
Revenue recognized			755	5,321
Additional development milestone payments		10,000
Development milestone payment included in contract liabilities	2,989		2,989
GSK | Belgium
Notes to the Consolidated Statements of Operations
Revenue recognized	€ 6,283	€ 19,295	€ 12,756	€ 43,041

X

- Definition

The amount of additional development milestone payment received.

+ References

No definition available.

+ Details

Name:	cvac_AdditionalDevelopmentMilestonePaymentsReceived
Namespace Prefix:	cvac_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of development milestone payment included in contract liabilities

+ References

No definition available.

+ Details

Name:	cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities
Namespace Prefix:	cvac_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2022-03-24
-Paragraph 114
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_114&doctype=Standard
-URIDate 2022-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2022-03-24
-Paragraph 113
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_113_a&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	ifrs-full_ProductsAndServicesAxis=cvac_MilestoneRevenuesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_GeographicalAreasAxis=country_BE
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: